Effect of lercanidipine and its (R)-enantiomer on atherosclerotic lesions induced in hypercholesterolemic rabbits

被引:23
作者
Soma, MR
Natali, M
Donetti, E
Baetta, R
Farina, P
Leonardi, A
Comparato, C
Barberi, L
Catapano, AL
机构
[1] Univ Milan, Inst Pharmacol Sci, I-20133 Milan, Italy
[2] Univ Milan, Ctr Studio Prevenz & Terapia Vasculopatie Aterosc, I-20122 Milan, Italy
[3] Recordati SpA, Div Pharmaceut Res & Dev, Milan, Italy
关键词
calcium antagonists; lercanidipine; atherosclerosis; animal model; smooth muscle cell proliferation; fatty-streaks; intimal hyperplasia;
D O I
10.1038/sj.bjp.0702221
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1 The in vivo antiatherogenic activity of the calcium antagonist lercanidipine and its (R)-enantiomer was investigated in two different types of atherosclerotic lesions (hyperplastic and fatty-streak lesions) in rabbits. 2 Lercanidipine (0.3, 1, and 3 mg kg(-1) week(-1)) as well as its (R)-enantiomer at 3 mg kg(-1) week(-1) were given by subcutaneous injection for 10 weeks to White New Zealand rabbits, with cholesterol feeding beginning at week 2. The hyperplastic lesion was obtained by positioning a hollow silastic collar around one carotid artery, while aortic fatty streak lesions were induced by cholesterol feeding. In untreated animals (n = 5), 14 days after collar positioning an intimal hyperplasia was clearly detectable: the arteries without collar showed a intima/media (I/M) ratio of 0.03+/-0.02, whereas in carotids with a collar the ratio was 2+/-0.42. In lercanidipine-treated animals a significant and dose-dependent effect on intimal hyperplasia was observed. I/M ratios were 0.73+/-0.4, 0.42+/-0.1, 0.32+/-0.1 for 0.3, 1, and 3 mg kg(-1) week(-1), respectively (P<0.05). The lercanidipine enantiomer (3 mg kg(-1) week(-1)) was as effective as the racemate (0.41+/-0.11). Proliferation of-smooth muscle cells, assessed by incorporation of BrdU into DNA, was reduced by about 50%, 70%, 85%, and 80% by lercanidipine (0.3, 1, and 3 mg kg(-1) week(-1)) and its (R)-enantiomer, respectively. 3 The area of fatty-streaks in the aorta (n=11-15) was significantly reduced by lercanidipine (3 mg kg(-1) week(-1), 16% vs 27%, P<0.05), a trend was observed also with lower doses. When different segments of the aorta were considered (arch, thoracic, abdominal) a significant and dose-dependent effect in the thoracic and abdominal aorta was observed also at lower doses. The (R)-enantiomer was as effective as lercanidipine. 4 These results suggest a direct antiatherosclerotic effect of lercanidipine, independent of modulation of risk factors such as hypercholesterolemia and/or hypertension as demonstrated by the absence of stereoselectivity.
引用
收藏
页码:1471 / 1476
页数:6
相关论文
共 41 条
[1]   EFFECTS OF LACIDIPINE ON EXPERIMENTAL-MODELS OF ATHEROSCLEROSIS [J].
BERNINI, F ;
CORSINI, A ;
RAITERI, M ;
SOMA, MR ;
PAOLETTI, R .
JOURNAL OF HYPERTENSION, 1993, 11 :S61-S66
[2]  
BERNINI F, 1991, J CARDIOVASC PHARM, V18, pS42
[3]  
BERNINI F, 1993, MED SCI SYMP SER, V3, P157
[4]   EFFECTS OF CALCIUM-ANTAGONISTS ON LIPIDS AND ATHEROSCLEROSIS [J].
BERNINI, F ;
CATAPANO, AL ;
CORSINI, A ;
FUMAGALLI, R ;
PAOLETTI, R .
AMERICAN JOURNAL OF CARDIOLOGY, 1989, 64 (17) :I129-I134
[6]  
CATAPANO AL, 1988, ANN NY ACAD SCI, V522, P519
[7]  
Catapano AL, 1997, EUR HEART J, V18, pA80
[8]  
CATAPANO AL, 1992, J CARDIOVASC PHAR SA, V20, pS44
[9]  
CLELAND JGF, 1993, BRIT HEART J, V69, pS54
[10]   Effect of the new calcium antagonist lercanidipine and its enantiomers on the migration and proliferation of arterial myocytes [J].
Corsini, A ;
Bonfatti, M ;
Quarato, P ;
Accomazzo, MR ;
Raiteri, M ;
Sartani, A ;
Testa, R ;
Nicosia, S ;
Paoletti, R ;
Fumagalli, R .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1996, 28 (05) :687-694